Here are four things to know.
1. The FDA approved 46 new drugs, agents or therapeutic biologics in 2017. Sixteen of the 46, or about 35 percent, are classified as personalized medicines.
2. In 2016, 13 of 45 new drug approvals were personalized medicines.
3. This marks the first time in history that the number of personalized medicines approved in a year topped 30 percent. Ten years ago, personalized medicines accounted for less than 10 percent of new drug approvals.
4. In 2017, the FDA approved the first gene therapy for use in the U.S. Now, three gene therapies have been approved for use.
To read the full report, click here.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
FDA approves treatment for digestive tract cancers: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
